Flow tDCS Headset & App
Major Depressive Disorder (MDD)
ApprovedActive
Key Facts
About Flow Neuroscience
Flow Neuroscience commercializes an at-home, prescription tDCS headset and digital therapeutic app for major depressive disorder (MDD). The technology, backed by over 25 years of clinical research, delivers gentle electrical stimulation to modulate brain activity linked to mood regulation, supported by a companion app providing behavioral therapy. The company has transitioned from clinical validation to commercial rollout, with real-world data from over 14,000 users and a pivotal RCT published in Nature Medicine supporting its efficacy claims. Its business model is direct-to-consumer (DTC) with a medical device certification, positioning it in the growing digital therapeutics and neuromodulation space.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |